Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and accounted for around 85% of all lung cancers in the United States.
In 2020, there will be an estimated 509,361 cases of NSCLC in the 7 main markets including the United States, Germany, France, Italy, Spain, the UK, and Japan. The NSCLC market is projected to rise at a compound annual growth rate (CAGR) of 10.7% from 2017 to 2040, according to Non-Small Cell Lung Cancer (NSCLC) Market Insights, Epidemiology, and Market Forecast 2030 by DelveInsight, a market research firm focused exclusively on the life sciences.
There are several treatment options available to treat this condition. Typically, chemotherapy, targeted treatments, and immunotherapy—alone or in combination—are used to treat lung cancer. Besides pharmacological treatment choices, surgery and radiation are also frequently opted.
One of the most exciting developments in lung cancer medicine is the introduction of targeted treatments. Unlike chemotherapy drugs, which cannot tell the difference between normal cells and cancer cells, targeted therapies are designed to attack cancer cells specifically by attaching to or blocking targets that appear on the surfaces of those cells. People who have advanced lung cancer with certain molecular biomarkers may receive treatment with a targeted drug alone or in combination with chemotherapy.
As several institutes and pharmacological companies have devoted themselves to a more in-depth understanding of this disease, therapies for advanced NSCLC have developed significantly with a new awareness of histologic subtypes.
In the coming years, the non-small cell lung cancer market is expected to shift due to rising awareness of the disease and incremental healthcare spending across the globe, which would expand the size of the market to enable great penetration for drug manufacturers.
Where to Learn More
Non-Small Cell Lung Cancer (NSCLC) - Market Insights, Epidemiology and Market Forecast - 2030 delivers an in-depth review of the Non-Small Cell Lung Cancer, historical and forecasted epidemiology as well as the non-small cell lung cancer market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.
This market report provides current treatment practices, emerging drugs, non-small cell lung cancer market share of the individual therapies, current and forecasted non-small cell lung cancer market size from 2017 to 2030 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.
Visit MarketResearch.com to read the full report description and learn more.
About the Publisher: DelveInsight is a market research firm focused exclusively on the life sciences. It provides cutting-edge market and pipeline information to help organizations make important business decisions and identify potential market opportunities.
